RNU6ATAC17P

Across TCGA pan-cancer cohorts, RNU6ATAC17P RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RNU6ATAC17P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where RNU6ATAC17P RNA is repressed in tumor relative to normal tissue. In most cancer types RNU6ATAC17P is over-expressed in tumor, although a few such as KIRP show the opposite, repressed pattern.

KIRP, LIHC, and LUAD are the cancer types where RNU6ATAC17P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6ATAC17P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	IV	−0.415	.025	3	view →
LIHC	Female	All	+0.208	.043	2	view →
LUAD	Male	All	+0.359	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

RNU6ATAC17P–KIRP

Open the KIRP breakdown →